Identification, characterization, and structure verification of impurities, detected throughout the stages of drug discovery and development, involve large collaborative efforts to process and interpret large volumes of data. Loss of disparate information, gathered over long timeframes across various techniques and data formats, can lead to inefficiencies such as duplicated efforts and wasted time.
Accelerate impurity profiling by using ACD/Labs flexible collection software tools to understand data from multiple analytical techniques, including LC/UV, LC/MS, NMR, and more. Use technique-specific modules to process data from a variety of vendor formats away from the instrument. Easily interpret and track impurity results by applying all your chemical knowledge.
"Have we seen this impurity before?" ACD/Labs software will centralize access to experimental data and results allowing you to leverage existing chemical information to quickly identify known impurities and hypothesize the unknown structures.
Quickly characterize impurities to support drug or chemical compound submissions to the FDA, TPD, or other regulatory bodies. Support the qualification of impurities with easy-to-generate reports that provide traceability, linking individual impurities or impurity profiles to experimental results across numerous techniques. For the impurities within the specified TTC% (Threshold of Toxicological Concern), apply in-silico predictions to assess toxicity endpoints, such as genotoxicity, hERG inhibition, hepatotoxicity (CYP 450 Inhibition), when toxicological data are limited or lacking.
ACD/Labs' software solution for REACH provides accurate and reliable physicochemical and toxicological property predictions with systematic nomenclature for chemical structures.
ACD/AutoChrom manages projects and optimizes and executes the experiments; guiding you through data processing and interpretation to select the most stable and effective chromatographic method. Develop better, more robust methods, in less time than you ever could before.